Contact Us
Drug Search Results
More Filters [+]

Empagliflozin

Alternative Names: empagliflozin, jardiance, bi 10773, bi10773, bi-10773, synjardy xr, trijardy xr, glyxambi, synjardy, VORETA
Latest Update: 2024-12-18
Latest Update Note: Clinical Trial Update

Product Description

Empagliflozin is an orally available competitive inhibitor of sodium-glucose co-transporter 2 (SGLT2; SLC5A2) with antihyperglycemic activity. Upon oral administration, empagliflozin selectively and potently inhibits SGLT2 in the kidneys, thereby suppressing the reabsorption of glucose in the proximal tubule.

Mechanisms of Action: SGLT2 Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Approved

Approved Countries: Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Canada | Chile | China | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Mexico | Netherlands | New Zealand | Norway | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam

Approved Indications: Heart Failure | Acidosis | Diabetic Ketoacidosis | General Diabetes | Type 2 Diabetes | Type 1 Diabetes | Acidosis | Diabetic Ketoacidosis | General Diabetes | Type 2 Diabetes | Pancreatitis | Type 1 Diabetes | Acidosis | Diabetic Ketoacidosis | General Diabetes | Type 2 Diabetes | Pancreatitis | Type 1 Diabetes | Acidosis | Diabetic Ketoacidosis | General Diabetes | Type 2 Diabetes

Known Adverse Events: Urinary Tract Infections | Headache | Asthenia | Diarrhea | Flatulence | Nasopharyngitis | Pharyngitis | Enteritis | Gastroenteritis | Respiratory Tract Infections | Constipation

Company: Boehringer Ingelheim
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Empagliflozin

Countries in Clinic: Argentina, Australia, Belgium, Brazil, Bulgaria, Canada, China, Colombia, Czech Republic, Denmark, Finland, France, Germany, Greece, Hungary, India, Israel, Italy, Japan, Jordan, Korea, Malaysia, Mexico, Netherlands, Norway, Peru, Philippines, Poland, Portugal, Puerto Rico, Romania, Russia, Serbia, Singapore, Slovenia, South Africa, Spain, Sweden, Switzerland, Taiwan, Thailand, Ukraine, United Kingdom, United States, Unknown Location

Active Clinical Trial Count:

Highest Development Phases

Phase 3: Diabetes, Gestational|Heart Failure|Heart Failure, Acute|Heart Failure, Chronic|Kidney Diseases|Kidney Failure, Chronic|Myocardial Infarction|Shock, Cardiogenic|Tricuspid Valve Insufficiency|Type 2 Diabetes

Phase 2: Kidney Calculi|Liver Cirrhosis|Liver Failure|Nephrolithiasis

Phase 1: General Diabetes|Healthy Volunteers

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
U1111-1306-5049

P3

Recruiting

Kidney Failure, Chronic

2028-08-30

1378-0006

P3

Unknown Status

Kidney Diseases

2028-07-01

U1111-1302-4422

P3

Recruiting

Heart Failure

2027-11-15

1378-0020

P3

Unknown Status

Heart Failure

2027-11-05

Recent News Events

Date

Type

Title

12/19/2024

News Article

 Diabetes Brands Dexcom, Ozempic, Mounjaro Drive Q3 Convergent TV Ad Engagement

11/19/2024

News Article

 Cardiovascular Researchers Dramatically Reduce Size and Severity of Stroke Using Antidiabetic Drug in Preclinical Models

11/15/2024

News Article

 Inventiva will present data from the final analysis of the Phase 2 study evaluating the combination of lanifibranor with empagliflozin in patients with MASH and T2D at the AASLD The Liver Meeting® late-breaker session

10/24/2024

News Article

 Medera Announces Completion of Cohort A and Initiation of Dosing in Cohort B of MUSIC-HFpEF, a Phase 1/2a Clinical Trial Evaluating First-In-Human Gene Therapy SRD-002 for Heart Failure with Preserved Ejection Fraction

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions